Biorce Raises $5.9M to Revolutionize Clinical Trials with AI-Driven Jarvis

Biorce is thrilled to announce a major funding milestone as we raise $5,900,000 to accelerate our mission of revolutionizing clinical trials. Founded on the belief that bold thinking transforms complex challenges into groundbreaking solutions, Biorce continues to lead the industry with Jarvis by Biorce, the world’s first AI protocol assistant meticulously engineered for clinical research. This significant investment will enable us to further refine Jarvis, which has already been a game-changer for biotech, pharma, and CROs by streamlining protocol design and driving smarter, faster trials without compromising on accuracy, compliance, or quality. Jarvis, trained on over 500,000 global studies, offers robust features such as proven endpoint suggestions, real-time feasibility checks, regulatory alignment, and actionable insights backed by credible sources. With this funding, we plan to invest in expanding our research and development capabilities, enhancing our AI algorithms, and scaling our technology to support an even larger user base. We believe that faster trials do not equate to riskier ones; rather, they create opportunities for smarter, data-driven decisions that minimize waste, reduce amendments, and maintain the highest standards of patient care. At Biorce, every protocol refined and every patient impacted reinforces our commitment to transforming the clinical trial landscape—one protocol at a time and one patient at a time. This new capital injection marks just the beginning of our journey toward helping research teams worldwide overcome clinical trial complexity with ingenuity and precision. We look forward to sharing more exciting developments as we continue to shape the future of clinical research.